Aminocaproic acid (injection)

Revision as of 21:46, 29 January 2014 by ShiSheng (talk | contribs)
Jump to navigation Jump to search
Aminocaproic acid
AMICAR® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

For patient information, click here.

Overview

Aminocaproic acid (also known as Amicar, є-amino caproic acid, or 6-aminohexanoic acid) is a derivative and analogue of the amino acidlysine, which makes it an effective inhibitor for enzymes which bind that particular residue. Such enzymes includeproteolytic enzymes (which break down proteins) including plasminogen, the enzyme responsible for fibrinolysis. For this reason it is effective in treatment of some bleeding disorders and is marketed as Amicar.

Category

Antifibrinolytics

US Brand Names

AMICAR®

FDA Package Insert

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

Aminocaproic acid works as an anti-fibrinolytic or anti-proteolytic. As a lysine analogue, it binds reversibly to the kringle domain of the enzyme plasminogen and blocks binding of fibrin, which is normally activated to plasmin.

References


Template:WikiDoc Sources